Psychedelics Intranasal delivery tech developer ‘Polyrizon’ plans to administer psychedelics The Israeli company has an unnamed new partner involved with unspecified psychedelic drugs Rowan DunneMarch 18, 2025
Psychedelics Mescaline drug developer Neural Therapeutics closes funding needed for CSE listing This company's primary focus is making an extract from San Pedro -- a psychedelic cactus Rowan DunneMarch 14, 2025
Psychedelics MindBio Therapeutics uses AI speech analysis to see if you’ve taken its LSD drug The biopharma operator's lead drug candidate, MB22001, was created for microdosing Rowan DunneJanuary 24, 2025
Medical and Pharmaceutical bioAffinity Technologies secures Australian patent for ‘CyPath Lung’ spit test It will be issued within 3 months provided that there are no opposition filings made by third parties Rowan DunneJanuary 22, 2025
Cyber Security Cybersecurity specialist BIO-key soars on major contract with Egypt’s largest bank BIO-key will provide the National Bank of Egypt with access to its PortalGuard identify management platform Rowan DunneJanuary 15, 2025
Science and Research IGM Biosciences slides by 66% on discontinued drug development and lay offs The biotech company has put the halt on 2 therapeutics used to treat arthritis, lupus and myasthenia gravis Rowan DunneJanuary 10, 2025
Medical and Pharmaceutical SILO Pharma flies high on impending patent for intranasal PTSD drug The stock rose by 146% in early morning trading on the Nasdaq Rowan DunneJanuary 8, 2025
Medical and Pharmaceutical Hoth Therapeutics up over 218% on dermatology breakthrough for cancer patients The biopharma operator's 'HT-001" drug was highly successful in alleviating skin issues caused by a cancer treatment Rowan DunneJanuary 7, 2025
Medical and Pharmaceutical RAPT Therapeutics sees 113% spike on allergy med licensing deal & private placement The biotech operator can develop and commercialize Jemincare's food allergy medication throughout most of the world Rowan DunneDecember 23, 2024
Cannabis Weedmaps parent company stock spikes after proposition to go private The multi-purpose cannabis platform operator has been on a steady decline since it went public in 2021 Rowan DunneDecember 18, 2024